CD73/Ecto-5′-nucleotidase protects against vascular inflammation and neointima formation

Circulation

Volumn 113, Issue 17, 2006, Pages 2120-2127

  Zernecke, Alma ^a   Bidzhekov, Kiril ^a   Özüyaman, Burcin ^a,b   Fraemohs, Line ^a   Liehn, Elisa A ^a   Lüscher Firzlaff, Juliane M ^a   Lüscher, Bernhard ^a   Schrader, Jürgen ^b   Weber, Christian ^a,c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Cell adhesion molecules; Endothelium; Lesion; Leukocytes

Indexed keywords

4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; 5' NUCLEOTIDASE; ADENOSINE; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CELL ADHESION MOLECULE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; SYNAPTOTAGMIN; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; CAROTID ARTERY; CELL ACTIVATION; CELL ADHESION; CELL CYCLE ARREST; CELL MIGRATION; CHROMATIN STRUCTURE; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; EX VIVO STUDY; GENE EXPRESSION; IMMUNOPRECIPITATION; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; ANIMAL; ATHEROSCLEROSIS; GENETICS; HYPERPLASIA; INTIMA; MALE; PATHOLOGY; PHYSIOLOGY; VASCULITIS;

5'-NUCLEOTIDASE; ANIMALS; ATHEROSCLEROSIS; HYPERPLASIA; INTEGRIN ALPHA4BETA1; MALE; MICE; MONOCYTES; NF-KAPPA B; TUNICA INTIMA; VASCULAR CELL ADHESION MOLECULE-1; VASCULITIS;

EID: 33646456788     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.595249     Document Type: Article

References (30)

1. Zimmermann H. 5′-Nucleotidase: molecular structure and functional aspects. Biochem J. 1992;285:345-365.
2. Deussen A, Bading B, Kelm M, Schrader J. Formation and salvage of adenosine by macrovascular endothelial cells. Am J Physiol. 1993;264:H692-H700.
3. Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol. 1997;79:2-10.
4. Sullivan GW. Adenosine A2A receptor agonists as anti-inflammatory agents. Curr Opin Investig Drugs. 2003;4:1313-1319.
5. Bouma MG, van den Wildenberg FA, Buurman WA. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol. 1996;270:C522-C529.
6. Morandini R, Ghanem G, Portier-Lemarie A, Robaye B, Renaud A, Boeynaems JM. Action of cAMP on expression and release of adhesion molecules in human endothelial cells. Am J Physiol. 1996;270:H807-H816.
7. Walker G, Langheinrich AC, Dennhauser E, Bohle RM, Dreyer T, Kreuzer J, Tillmanns H, Braun-Dullaeus RC, Haberbosch W. 3-Deazaadenosine prevents adhesion molecule expression and atherosclerotic lesion formation in the aortas of C57BL/6J mice. Arterioscler Thromb Vasc Biol. 1999;19:2673-2679.
8. McPherson JA, Barringhaus KG, Bishop GG, Sanders JM, Rieger JM, Hesselbacher SE, Gimple LW, Powers ER, Macdonald T, Sullivan G, Linden J, Sarembock IJ. Adenosine A(2A) receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler Thromb Vasc Biol. 2001;21:791-796.
9. Koszalka P, Ozuyaman B, Huo Y, Zernecke A, Flogel U, Braun N, Buchheiser A, Decking UK, Smith ML, Sevigny J, Gear A, Weber AA, Molojavyi A, Ding Z, Weber C, Ley K, Zimmermann H, Gödecke A, Schrader J. Targeted disruption of cd73/ecto-5′-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res. 2004;95:814-821.
10. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, Colgan SP. Crucial role for ecto-5′-nucleotidase (CD73) in vascular leakage during hypoxia J Exp Med. 2004;200:1395-1405.
11. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
12. Zernecke A, Schober A, Bot I, von Hundelshausen P, Liehn EA, Mopps B, Mericskay M, Gierschik P, Biessen EA, Weber C. SDF-1α/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res. 2005;96:784-791.
13. Kreisel D, Krupnick AS, Szeto WY, Popma SH, Sankaran D, Krasinskas AM, Amin KM, Rosengard BR. A simple method for culturing mouse vascular endothelium. J Immunol Methods. 2001;254:31-45.
14. Weber C, Erl W, Pietsch A, Strobel M, Ziegler-Heitbrock HW, Weber PC. Antioxidants inhibit monocyte adhesion by suppressing NF-κB mobilization and induction of VCAM-1 in endothelial cells stimulated to generate radicals. Arterioscler Thromb. 1994;14:1665-1673.
15. Vervoorts J, Lüscher-Firzlaff JM, Rottmann S, Lilischkis R, Walsemann G, Dohmann K, Austen M, Lüscher B. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep. 2003;4:484-490.
16. Schober A, Zernecke A, Liehn EA, von Hundelshausen P, Knarren S, Kuziel WA, Weber C. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. Circ Res. 2004;95:1125-1133.
17. Minguet S, Huber M, Rosenkranz L, Schamel WW, Reth M, Brummer T. Adenosine and cAMP are potent inhibitors of the NF-κB pathway downstream of immunoreceptors. Eur J Immunol. 2005;35:31-41.
18. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J. 1995;9:899-909.
19. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-κB and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol. 2000;20:E83-E88.
20. Huo Y, Hafezi-Moghadam A, Ley K. Role of VCAM-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions. Circ Res. 2000;87:153-159.
21. Davis C, Fischer J, Ley K, Sarembock TJ. The role of inflammation in vascular injury and repair. J Thromb Haemost. 2003;1:1699-1709.
22. Eltzschig HK, Thompson LF, Karhausen J, Cotta RJ, Ibla JC, Robson SC, Colgan SP. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood. 2004;104:3986-3992.
23. Peter K, Weirich U, Nordt TK, Ruef J, Bode C Soluble VCAM-1 as potential marker of atherosclerosis. Thromb Haemost. 1999;82(suppl 1):38-43.
24. Sullivan GW, Lee DD, Ross WG, DiVietro JA, Lappas CM, Lawrence MB, Linden J. Activation of A2A adenosine receptors inhibits expression of α4β1 integrin (VLA-4) on stimulated human neutrophils. J Leukoc Biol. 2004;75:127-134.
25. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNF-α, and nitric oxide production in RAW264.7 macrophages and in endotoxemic mice. J Immunol. 1996;157:4634-4640.
26. Zernecke A, Weber C. Inflammatory mediators in atherosclerotic vascular disease. Basic Res Cardiol. 2005;100:93-101.
27. Lennon PF, Taylor CT, Stahl GL, Colgan SP. Neutrophil-derived 5′-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med. 1998;188:1433-1443.
28. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003;349:2316-2325.
29. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology, XXV: nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527-552.
30. Sanada S, Asanuma H, Minamino T, Node K, Takashima S, Okuda H, Shinozaki Y, Ogai A, Fujita M, Hirata A, Kim J, Asano Y, Mori H, Tomoike H, Kitamura S, Hori M, Kitakaze M. Optimal windows of statin use for immediate infarct limitation: 5′-nucleotidase as another downstream molecule of phosphatidyl-inositol 3-kinase. Circulation. 2004;110:2143-2149.